Favipiravir and/or nitazoxanide: a randomized, double-blind, 2 ×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
DiscussionWe propose to conduct a proof-of-principle placebo-controlled clinical trial of favipiravir plus or minus nitazoxanide in health workers, their household members and patients treated at the Mexican Social Security Institute (IMSS) facilities. Participants with or without symptomatic COVID-19 or who tested positive will be assigned to receive favipiravir plus nitazoxanide or favipiravir plus nitazoxanide placebo. The primary outcome will be the difference in the amount of virus ( ‘viral load’) in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalization, major morbidi...
Source: Trials - July 22, 2022 Category: Research Source Type: clinical trials
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
Condition: Influenza, Pandemic Interventions: Biological: BW-1014: 25 µg rH5 in 20% NE - pipette - IN; Biological: BW-1014: 50 µg rH5 in 20% NE - pipette - IN; Biological: BW-1014: 100 µg rH5 in 20% NE - pipette - IN; Biological: rH5 (100 µg) control - pipette - IN; Biological: Saline (Placebo) - pipette - IN; Biological: H5N1 IIV - IM Sponsors: BlueWillow Biologics; University of Maryland, Baltimore; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2022 Category: Research Source Type: clinical trials
